Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug SGR-2921 tested for tough blood cancers – but trial halted early

NCT ID NCT05961839

Disease control Sponsor: Schrödinger, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested an experimental oral drug called SGR-2921 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The main goals were to check safety and find the right dose. However, the study was terminated early, so no results are available yet.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SGR-2921 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat blood cancers.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so we don't know if the drug is safe or effective. Many early-stage drugs never make it to patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

66 people

The number who actually took part.

Started

Sep 2023

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years of age. * Life expectancy ≥ 8 weeks. * Confirmed diagnosis of R/R AML or High Risk (HR) and Very High Risk (VHR) MDS. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. Exclusion Criteria: * Active malignancies within two years prior to the first dose, or requiring ongoing treatment, not related to AML or MDS. * Clinical evidence of central nervous system (CNS) or pulmonary leukostasis, ≥ Grade 3 disseminated intravascular coagulation, or active CNS leukemia. * Use of experimental drug, or therapy, or anti-cancer therapy within 14 days or 5 half-lives of the first dose of study drug. * QT interval corrected for heart rate per Fridericia's formula ≥470 msec during screening ECG.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia High-risk and very high-risk myelodysplastic syndromes

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Oncology Associates of Oregon, P.C.

    Eugene, Oregon, 97401, United States

  • Oregon Health & Science University - Knight Cancer Institute - Center of Hematologic Malignancies

    Portland, Oregon, 97239, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • St. David's South Austin Medical Center

    Austin, Texas, 78745, United States

  • The Ohio State University Wexner Medical Center - James Cancer Hospital

    Columbus, Ohio, 43210, United States

  • The University of Kansas Clinical Research Center

    Fairway, Kansas, 66205, United States

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization

    Philadelphia, Pennsylvania, 19107, United States

  • TriStar Bone Marrow Transplant, LLC

    Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.